Losartan potassium, an angiotensin II receptor antagonist, is the first of a new class of
agents to be introduced for the treatment of hypertension. In this review, we describe the …

Synopsis Losartan potassium is an orally active, nonpeptide angiotensin II (AII) receptor
antagonist. It is the first of a new class of drugs to be introduced for clinical use in …

Aim: To examine the safety profile and tolerability of losartan potassium (losartan), a
selective antagonist of the angiotensin II type 1 (AT 1) receptor Patients and methods …

Objective To describe a new class of antihypertensive agents, the angiotensin II receptor
antagonists, with emphasis on the prototype losartan. Pharmacokinetic data and clinical …

Losartan is a novel orally active nonpeptidal antihypertensive agent that specifically blocks
the angiotensin II type I receptor. This paper compares the short-and long-term safety and …

Angiotensin receptor antagonists represent a new class of drugs for the treatment of patients
with hypertension. Reduction of blood pressure in patients with essential hypertension …

Blockade of angiotensin II receptors was first achieved in the 1970s using a peptide,
saralasin acetate. Although it was effective in lowering blood pressure, it required parenteral …

Losartan is an orally active, nonpeptide, selective angiotensin subtype 1 (AT 1) receptor
antagonist. It provides a more specific and complete blockade of the actions of angiotensin II …

This report presents data on the safely and tolerabilify of losartan potassium (losartan), a
selective antagonist of the angiotensin II AT-1 receptor, in approximately 2,900 hypertensive …

Introduction: Blockade of the renin-angiotensin system is one of the major therapeutic
strategies in the management of patients with essential hypertension, congestive heart …